Upadacitinib: A Convenient and Effective Alternative Treatment for Spondyloarthritis

By Staff Writer

February 3, 2023

Treatment guidelines for adults with active non-radiographic axial spondyloarthritis recommend the use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Tumor Necrosis Factor-alpha (TNF-alpha) inhibitors. If these first-line treatments don’t work or aren’t suitable, doctors may consider secukinumab or ixekizumab (IL-17 inhibitors). Clinical trials show that upadacitinib, an oral Janus Kinase (JAK) inhibitor, can reduce symptoms and improve the quality of life in Spondyloarthritis (SpA) patients. This effectiveness rivals that of biologics. Clinicians use the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score and/or Visual Analogue Scale (VAS) score to measure this. A cost comparison shows that upadacitinib costs about the same and provides similar health benefits as secukinumab and ixekizumab.

The update suggests considering upadacitinib as an alternative to the National Institute for Health and Care Excellence (NICE) recommended Interleukin (IL)-17 inhibitors. This is especially important if conventional therapy doesn’t control the condition well enough or if TNF-alpha inhibitors aren’t suitable or effective.

Clinical and patient experts highlighted the convenience of upadacitinib over IL-17 inhibitors owing to its oral administration.

Reference url

Recent Posts

Navigating Challenges for Small Countries to Access Innovative Medicines

By João L. Carapinha

July 31, 2025

Access to innovative medicines is a pressing issue for patients in smaller European countries. These nations often face significant barriers in obtaining timely and equitable healthcare solutions. The article "Ensuring access to innovative medicines for patients in smaller countries" (linked belo...
Mental Health Policy Integration: A Cross-Sector Imperative for Well-being and Productivity
The purpose of this update is to review a recent Lancet editorial (linked below) on mental health policy integration in public policy frameworks. The article “Mental health in all policies” emphasizes that mental health influences individual well-being, societal cohesion, and economic productivit...
Novartis Gains Approval for Groundbreaking Malaria Treatment for Infants

By Rene Pretorius

July 30, 2025

In this article we review Swissmedic's approval of Novartis' Coartem Baby. It is the first malaria treatment for infants under 4.5 kilograms. This novel formulation addresses a critical gap in antimalarial care. Existing treatments were unsuitable due to dosing and metabolism concerns in young in...